Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 16Triple Negative Breast Neoplasms 5Stomach Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4Esophageal Neoplasms 4Adenocarcinoma Of Esophagus 4Neoplasms 3Neoplasm Metastasis 3Nasopharyngeal Carcinoma 3Adenocarcinoma 3Colorectal Neoplasms 2Biliary Tract Neoplasms 2Rectal Neoplasms 1Pancreatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Locally Advanced Gastric Cancer 1Glioblastoma 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1Clinical Stage I Gastric Cancer AJCC v8 1Childhood Solid Tumor 1Breast Neoplasm Malignant Female 1Brain Neoplasms 1Advanced Solid Tumour 1Advanced Rectal Cancer 1Adjuvant Drug Therapy 1

Interventions

pembrolizumab 18Specimen Handling 16Magnetic Resonance Spectroscopy 11Biopsy 11Paclitaxel 8Carboplatin 8trastuzumab deruxtecan 6Pemetrexed 6Nivolumab 6Irinotecan 6Fulvestrant 6Bevacizumab 6Radiosurgery 5Leucovorin 5Gemcitabine 5Fluorouracil 5Cetuximab 5palbociclib 4Oxaliplatin 4Letrozole 4Cisplatin 4olaparib 3durvalumab 3Taxes 3Ipilimumab 3Docetaxel 3Capecitabine 3130-nm albumin-bound paclitaxel 3sacituzumab govitecan 2ribociclib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasm Metastasis × Capecitabine × 30 days × Clear all
NCT07007559 2026-06-05

ASPEN-09-03

ALX Oncology Inc.

Phase 2 Recruiting
120 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT06247995 2026-05-27

NeoB-Cap1

Novartis

Phase 1/2 Recruiting
58 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT05374512 2026-05-15

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

AstraZeneca

Phase 3 Active not recruiting
644 enrolled 1 FDA
Breast

Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡